drugset / Trial / NCT02302716

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

NCT02302716

Phase 3 Completed 493 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications (OAMs).

Timeline

Start
2014-12
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2963016 Protein / enzyme biologic 10 iu Subcutaneous
Comparator insulin glargine Protein / enzyme biologic 10 iu Subcutaneous